4-(1-Aminoethyl)-1-pyridin-4-ylcyclohexane-1-carboxamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(1-Aminoethyl)-1-pyridin-4-ylcyclohexane-1-carboxamide
• 英文别名: 4-(1-aminoethyl)-1-pyridin-4-ylcyclohexane-1-carboxamide
• 化学式: C₁₄H₂₁N₃O
• 分子量: 247.34
• InChiKey: YJBRMEAXBFZOOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM
  申请人：Kyoto Prefectural Public University Corporation

  公开号：EP3064222A1

  公开（公告）日：2016-09-07

  The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

  本发明提供了一种治疗药物或预防药物，用于治疗与内质网（ER）应激有关的疾病、失调或病症。具体来说，本发明提供了一种治疗药物或预防药物，用于治疗与角膜上皮细胞内质网（ER）应激有关的疾病、失调或病症，该药物含有一种 TGFβ 信号抑制剂。作为一种优选的 TGFβ 信号抑制剂，该药物含有 4-[4-(1,3-苯并二恶茂-5-基)-5-(2-吡啶基)-1H-咪唑-2-基]苯甲酰胺。
• NOVEL TREATMENT OF CORNEA USING LAMININ
  申请人：Kyoto Prefectural Public University Corporation

  公开号：EP3213762A1

  公开（公告）日：2017-09-06

  The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or a fragment of these.

  本发明提供了一种治疗角膜的技术。更具体地说，本发明是一种用于治疗或预防角膜内皮疾病状态的药剂，该药剂包括至少一种选自由层粘连蛋白及其片段组成的组中的因子，其中问题的解决还在于提供了一种技术，其特征在于该药剂与角膜内皮细胞一起给药。具体来说，本发明可包括层粘连蛋白 511（α5β1γ1）、层粘连蛋白 521（α5β2γ1）或其片段。
• Combined agent for cell therapy of corneal endothelial cell
  申请人：KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

  公开号：US10959997B2

  公开（公告）日：2021-03-30

  The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.

  本发明提供了一种用于治疗或预防角膜内皮的疾病、失调或状况的制剂，所述制剂包括角膜内皮细胞和肌球蛋白II特异性抑制剂。更具体地说，肌球蛋白II特异性抑制剂是blebbistatin。该疾病、失调或病症通常是与福氏内皮角膜营养不良或角膜内皮功能障碍（大泡性角膜病）相关的失调。还提供了一种治疗或预防角膜内皮疾病的方法，所述方法包括向受试者施用有效量的肌球蛋白II特异性抑制剂和角膜内皮细胞。
• Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
  申请人：KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

  公开号：US11382904B2

  公开（公告）日：2022-07-12

  The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

  本发明提供了一种治疗药物或预防药物，用于治疗与内质网（ER）应激有关的疾病、失调或病症。具体来说，本发明提供了一种治疗药物或预防药物，用于治疗与角膜上皮细胞内质网（ER）应激有关的疾病、失调或病症，该药物含有一种 TGFβ 信号抑制剂。作为一种优选的 TGFβ 信号抑制剂，该药物含有 4-[4-(1,3-苯并二恶茂-5-基)-5-(2-吡啶基)-1H-咪唑-2-基]苯甲酰胺。
• NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS
  申请人：Kyoto Prefectural Public University Corporation

  公开号：EP2799537B1

  公开（公告）日：2021-09-22